2017
SURG-06. LASER ABLATION IN STEREOTACTIC NEUROSURGERY (LAISE): A MULTI-INSTITUTIONAL RETROSPECTIVE ANALYSIS OF LITT FOR BRAIN METASTASIS
Sloan A, Tatter S, Mohammadi A, Judy K, Prabhu S, Lovick D, Chamoun R, Chiang V, Leuthardt E. SURG-06. LASER ABLATION IN STEREOTACTIC NEUROSURGERY (LAISE): A MULTI-INSTITUTIONAL RETROSPECTIVE ANALYSIS OF LITT FOR BRAIN METASTASIS. Neuro-Oncology 2017, 19: vi236-vi236. PMCID: PMC5693010, DOI: 10.1093/neuonc/nox168.963.Peer-Reviewed Original ResearchBrain metastasesBrain tumorsMedian ECOG performance statusMulti-institutional retrospective analysisECOG performance statusMetastatic brain tumorsMedian survivalPerformance statusMedian ageNeurological deathInoperable tumorsRetrospective databaseTumor locationFrequent primaryRetrospective analysisInvasive proceduresAlternative treatmentPatientsDischarge statusMetastasisGliomasPrevious treatmentLaser interstitial thermotherapyTumorsTreatment
2016
The Effect of Gene Alterations and Tyrosine Kinase Inhibition on Survival and Cause of Death in Patients With Adenocarcinoma of the Lung and Brain Metastases
Sperduto PW, Yang TJ, Beal K, Pan H, Brown PD, Bangdiwala A, Shanley R, Yeh N, Gaspar LE, Braunstein S, Sneed P, Boyle J, Kirkpatrick JP, Mak KS, Shih HA, Engelman A, Roberge D, Arvold ND, Alexander B, Awad MM, Contessa J, Chiang V, Hardie J, Ma D, Lou E, Sperduto W, Mehta MP. The Effect of Gene Alterations and Tyrosine Kinase Inhibition on Survival and Cause of Death in Patients With Adenocarcinoma of the Lung and Brain Metastases. International Journal Of Radiation Oncology • Biology • Physics 2016, 96: 406-413. PMID: 27598807, PMCID: PMC5575932, DOI: 10.1016/j.ijrobp.2016.06.006.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAgedAged, 80 and overAnaplastic Lymphoma KinaseAntineoplastic AgentsBrain NeoplasmsErbB ReceptorsFemaleGenetic MarkersGenetic Predisposition to DiseaseHumansIncidenceLung NeoplasmsMaleMiddle AgedMutationPolymorphism, Single NucleotidePrevalenceProtein-Tyrosine KinasesReceptor Protein-Tyrosine KinasesRetrospective StudiesRisk FactorsSurvival RateUnited StatesConceptsTyrosine kinase inhibitionBrain metastasesMedian survivalCause of deathGene alterationsDiagnosis of BMMulti-institutional retrospective databaseTKI-naïve patientsRisk of deathLonger median survivalKinase inhibitionALK gene alterationsTreatment patternsCancer mortalityLung cancerPrimary diagnosisRetrospective databaseCommon causeLung adenocarcinomaGroup overallPatientsFirst treatmentPrior trialsEGFRMonths
2013
The effect of tumor subtype on the time from primary diagnosis to development of brain metastases and survival in patients with breast cancer
Sperduto PW, Kased N, Roberge D, Chao ST, Shanley R, Luo X, Sneed PK, Suh J, Weil RJ, Jensen AW, Brown PD, Shih HA, Kirkpatrick J, Gaspar LE, Fiveash JB, Chiang V, Knisely JP, Sperduto CM, Lin N, Mehta M. The effect of tumor subtype on the time from primary diagnosis to development of brain metastases and survival in patients with breast cancer. Journal Of Neuro-Oncology 2013, 112: 467-472. PMID: 23462853, DOI: 10.1007/s11060-013-1083-9.Peer-Reviewed Original ResearchConceptsNumber of BMBrain metastasesGraded Prognostic AssessmentPrimary diagnosisPrognostic factorsTumor subtypesMedian survivalBreast cancerDiagnosis-Specific Graded Prognostic AssessmentDevelopment of BMMulti-institutional retrospective databaseImportant prognostic factorIndependent prognostic factorBreast cancer patientsER/PRBreast cancer subtypesBreast-GPAProspective studyCancer patientsLuminal ALuminal BRetrospective databaseHER2 subtypeBrain MRIPrognostic assessment
2011
Summary Report on the Graded Prognostic Assessment: An Accurate and Facile Diagnosis-Specific Tool to Estimate Survival for Patients With Brain Metastases
Sperduto PW, Kased N, Roberge D, Xu Z, Shanley R, Luo X, Sneed PK, Chao ST, Weil RJ, Suh J, Bhatt A, Jensen AW, Brown PD, Shih HA, Kirkpatrick J, Gaspar LE, Fiveash JB, Chiang V, Knisely JP, Sperduto CM, Lin N, Mehta M. Summary Report on the Graded Prognostic Assessment: An Accurate and Facile Diagnosis-Specific Tool to Estimate Survival for Patients With Brain Metastases. Journal Of Clinical Oncology 2011, 30: 419-425. PMID: 22203767, PMCID: PMC3269967, DOI: 10.1200/jco.2011.38.0527.Peer-Reviewed Original ResearchConceptsGraded Prognostic AssessmentKarnofsky performance scoreBrain metastasesSignificant prognostic factorsPrognostic factorsPrognostic indexPrognostic assessmentMulti-institutional retrospective databasePerformance scoresPrognostic assessment indexOnly prognostic factorMedian survival timeRenal cell cancerSingle tumor typeExtracranial metastasesBetter prognosisCell cancerWorse prognosisGI cancersRetrospective databaseLung cancerClinical trialsAppropriate treatmentBreast cancerSurvival time